4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of “Moderate Buy” from Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has been assigned a consensus rating of “Moderate Buy” from the eleven analysts that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $30.40.

A number of research analysts have commented on FDMT shares. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Saturday, September 27th. Roth Capital decreased their price target on 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research note on Tuesday, August 12th. Finally, Chardan Capital restated a “buy” rating and set a $25.00 price target on shares of 4D Molecular Therapeutics in a research note on Tuesday, August 12th.

4D Molecular Therapeutics Stock Performance

Shares of 4D Molecular Therapeutics stock opened at $8.32 on Friday. The firm has a market capitalization of $388.54 million, a price-to-earnings ratio of -2.36 and a beta of 2.93. 4D Molecular Therapeutics has a fifty-two week low of $2.23 and a fifty-two week high of $9.52. The stock has a 50 day moving average of $6.89 and a 200 day moving average of $4.80.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.10). The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.52 million. 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%. Analysts forecast that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC lifted its stake in 4D Molecular Therapeutics by 1,103.4% during the first quarter. Acadian Asset Management LLC now owns 400,606 shares of the company’s stock worth $1,290,000 after purchasing an additional 367,317 shares in the last quarter. Harbor Capital Advisors Inc. acquired a new stake in shares of 4D Molecular Therapeutics in the first quarter valued at $99,000. Invesco Ltd. raised its stake in shares of 4D Molecular Therapeutics by 318.3% in the first quarter. Invesco Ltd. now owns 117,768 shares of the company’s stock valued at $380,000 after acquiring an additional 89,611 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of 4D Molecular Therapeutics in the first quarter valued at $63,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of 4D Molecular Therapeutics by 7.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company’s stock valued at $247,000 after acquiring an additional 2,925 shares in the last quarter. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.